IMPEL PHARMACEUTICALS INC (IMPL) Forecast, Price Target & Analyst Ratings

NASDAQ:IMPL • US45258K1097

Current stock price

0.2411 USD
-0.17 (-41.79%)
At close:
0.22 USD
-0.02 (-8.75%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IMPEL PHARMACEUTICALS INC (IMPL).

Forecast Snapshot

Consensus Price Target

Price Target
$40.80
+ 16,822.44% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q4 / 2023
EPS Estimate
-$0.21
Revenue Estimate
9.894M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
80.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$40.80
Upside
+ 16,822.44%
From current price of $0.24 to mean target of $40.80, Based on 8 analyst forecasts
Low
$40.40
Median
$40.80
High
$42.00

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

8 Wall Street analysts provided a forecast for the next 12 months for IMPL. The average price target is 40.8 USD. This implies a price increase of 16822.44% is expected in the next year compared to the current price of 0.2411.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

IMPL Current Analyst RatingIMPL Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

IMPL Historical Analyst RatingsIMPL Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8

Analyst Ratings Consensus

ChartMill Buy Consensus
80.00%
IMPL was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about IMPL.
In the previous month the buy percentage consensus was at a similar level.
IMPL was analyzed by 8 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2022-11-15WedbushDowngrade Outperform -> Neutral
2022-08-25JonesTradingInitiate Buy
2021-05-18GuggenheimInitiate Buy
2021-05-18WedbushInitiate Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q4 / 2023
EPS Estimate
-$0.21
Revenue Estimate
9.894M
Revenue Q2Q
97.49%
EPS Q2Q
77.92%
Number of Analysts
4

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
99,900.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

The next earnings revenue estimate has been revised upward by 99900% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2023 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
IMPL revenue by date.IMPL revenue by date.
670K12.65M
1,788.06%		29.274M
131.42%		51.918M
77.35%		82.314M
58.55%		239.7M
191.20%		300.9M
25.53%		351.9M
16.95%		402.9M
14.49%		453.9M
12.66%
EBITDA
YoY % growth
IMPL ebitda by date.IMPL ebitda by date.
-44.25M
-8.32%		-70.4M
-59.10%		-81.88M
-16.31%		-70.278M
14.17%		-48.144M
31.49%		-31.008M
35.59%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
IMPL ebit by date.IMPL ebit by date.
-45.33M
-9.04%		-71.49M
-57.71%		-83.08M
-16.21%		-71.094M
14.43%		-49.368M
30.56%		-32.232M
34.71%		81.396M
352.53%		123.22M
51.38%		156.37M
26.90%		189.52M
21.20%		222.67M
17.49%
Operating Margin
IMPL operating margin by date.IMPL operating margin by date.
N/A-10,670.15%-656.76%-242.86%-95.09%-39.16%33.96%40.95%44.44%47.04%49.06%
EPS
YoY % growth
IMPL eps by date.IMPL eps by date.
N/A-3.95-4.54
-14.94%		-1.61
64.50%		-0.89
44.94%		-0.59
33.33%		2.55
531.03%		2.86
12.00%		3.57
25.00%		4.28
20.00%		4.95
15.48%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-0.21
77.92%		-0.40
68.68%		-0.37
57.30%		-0.15
73.62%		-0.14
33.33%
Revenue
Q2Q % growth		9.894M
97.49%		10.2M
133.41%		12.24M
86.02%		13.77M
68.75%		15.708M
58.76%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-8.313M
54.17%		N/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

IMPL Yearly Revenue VS EstimatesIMPL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
IMPL Yearly EPS VS EstimatesIMPL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
23.19%
EPS Next 5 Year
21.33%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
85.83%
Revenue Next 5 Year
87.95%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
18.34%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

IMPEL PHARMACEUTICALS INC / IMPL Forecast FAQ

Can you provide the average price target for IMPEL PHARMACEUTICALS INC stock?

8 analysts have analysed IMPL and the average price target is 40.8 USD. This implies a price increase of 16822.44% is expected in the next year compared to the current price of 0.2411.

What are the consensus estimates for IMPL stock next earnings?

The consensus EPS estimate for the next earnings of IMPEL PHARMACEUTICALS INC (IMPL) is -0.21 USD and the consensus revenue estimate is 9.89M USD.

What is the consensus rating for IMPL stock?

The consensus rating for IMPEL PHARMACEUTICALS INC (IMPL) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.